ASH 2016 | Developments in multiple myeloma – immunotherapy and personalized medicine
Joseph Mikhael
• 3 Dec 2016
Joseph Mikhael, MD of the Mayo Clinic, Scottsdale, AZ talks about developments in multiple myeloma (MM) at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA. The area of immunotherapy continues to be very important with drugs such as venetoclax starting to play a role in myeloma. Prof. Mikhael highlights another important development: bone marrow samples are now taken at diagnosis and tested against different drugs to predict response. He believes that eventually we will be able to personalize therapy. At the Mayo Clinic for example, they have a program to sequence patients to better understand their inherent genetics.
